SEATTLE — Funding from the Chronic Disease Foundation impacts the decision to stay on a chosen therapy in patients with age-related macular degeneration, according to a poster presentation.
“Access to funding impacts a patient’s choice in what treatment they want to do, especially because anti-VEGF drugs are really expensive these days,” Cassie Papproth, BS, told Healio at the Association for Research in Vision and Ophthalmology meeting. “Most of the time, patients can’t afford them out of pocket.”
Researchers looked at how a two-week unfunded period